GlassScriptPhysician profile
Carlos A Delagarza
NPI 1225017122
$400.22
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.41 · 2020: $89.40 · 2021: $248.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $46.86 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $43.68 | 2020-2021 | |
| Lilly USA, LLC | $41.15 | 2020 | |
| Radius Health, INC. | $40.41 | 2019-2021 | |
| Amarin Pharma, INC. | $34.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.16 | 2021 | |
| Daiichi Sankyo INC. | $17.06 | 2021 | |
| Mylan Specialty L.P. | $16.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.19 | 2019 | |
| Abbvie INC. | $13.68 | 2021 | |
| Kaleo, INC. | $12.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2020 | |
| Eisai INC. | $11.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Delagarza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.